由于单克隆抗体(MoAb)能与造血系统肿瘤细胞表面的抗原相结合,发挥独特的细胞毒作用,不仅达到杀灭肿瘤细胞的目的,而且有效地防止了肿瘤细胞耐药的发生。因此,MoAb成为白血病和淋巴瘤免疫学治疗的重要制剂。某些研究者提出今后化疗世纪将被以MoAb为基础的治疗所取代。 Because monoclonal antibodies (MoAbs) can combine with the antigens on the surface of hematopoietic tumor cells and exert unique cytotoxic effects, they not only achieve the goal of killing tumor cells, but also effectively prevent the occurrence of tumor cell resistance. Therefore, MoAb is an important preparation for the immunological treatment of leukemia and lymphoma. Some researchers suggest that the future of chemotherapy will be replaced by MoAb-based therapies.